The collagen story nobody tells you

By your mid-30s, you're already losing about 1% of your collagen every year. That's slow enough that most women don't notice it happening. Then perimenopause arrives — and the rate jumps to around 5% per year. In the first five years after menopause, women can lose up to 30% of their skin collagen. Not gradually. Fast.

The reason is estrogen. Most people think of estrogen as a reproductive hormone. What's less discussed is its direct role in your skin. Estrogen binds to receptors on the skin cells that produce collagen — called fibroblasts. When those receptors are getting regular estrogen signals, fibroblasts stay active. When estrogen declines, fibroblast activity drops, and the enzymes that break down collagen start outpacing the ones that build it.

This affects more than how your skin looks. Collagen is structural tissue — it supports joints, bones, hair follicles, and connective tissue throughout your body. The accelerated loss during this period is one reason why women in perimenopause often notice changes across multiple systems at once, not just their skin.

What makes VERISOL® different from generic collagen

When we chose VERISOL® for SecondSpring, the decision came down to one word: specificity. Most collagen supplements sold in the Philippines are generic collagen hydrolysate — bovine or marine collagen that's been broken down into smaller fragments. These products are absorbable. But absorbable isn't the same as targeted.

VERISOL® is manufactured by GELITA AG in Germany using a proprietary enzymatic process that produces peptides at a precise 2.0 kDa molecular weight with a specific, reproducible peptide fingerprint. Every batch is validated by mass spectrometry. This isn't a quality assurance claim — it's what makes the clinical studies replicable. The product in the study and the product in your sachet are molecularly identical.

Generic collagen hydrolysates contain a random mix of peptide sequences — some bioactive, some not. VERISOL® is engineered to maximize the peptides that actually do the signaling work in skin fibroblasts.

What the research actually shows

VERISOL® has been tested in seven peer-reviewed clinical trials. The most cited is a randomized, double-blind, placebo-controlled study of 66 women aged 35–55 taking 2.5g daily for 8 weeks. These are the measured results:

A separate trial of 105 women over 6 months found a statistically significant reduction in skin surface roughness and measurable improvement in dermal density. A third study with 44 women aged 39–75 showed significantly increased hair follicle thickness after 16 weeks.

These results are not from the manufacturer's marketing materials — they're published in peer-reviewed journals and independently replicated. VERISOL® is also the first collagen ingredient to receive government health claim approval for skin elasticity in Japan, and regulatory approval for skin health claims in Brazil. That's regulatory validation, not self-declared efficacy.

Why 2.5g — and why that exact dose matters

SecondSpring contains 2.5g of VERISOL® per sachet. That's not a token amount chosen to put VERISOL® on the label — it's the exact dose used in all published clinical trials. This distinction matters more than it sounds.

When you see a supplement containing 500mg of collagen "with VERISOL®," that product may contain the branded ingredient but at a dose with no clinical evidence behind it. VERISOL® research has been conducted exclusively at 2.5g. Every study showing improved skin elasticity, reduced wrinkles, and increased procollagen content used this specific dose. There is no clinical data showing the same results at lower amounts.

The 2.5g dose also falls within what's called the "optimal biochemical threshold" for this peptide profile — the point where increasing the dose doesn't produce proportionally better results. Higher isn't more effective. 2.5g hits the threshold. That's the efficient dose — and it's what's in your sachet.

The bottom line

VERISOL® isn't in SecondSpring because it's trendy or because the packaging looks better with a clinical-sounding name. It's in there because it's the most rigorously researched collagen peptide ingredient available — with seven clinical trials, a reproducible molecular profile, government health claim approvals in multiple countries, and documented results in the age group our product is built for.

The estrogen-collagen connection is real. The window between 35 and 55 is real. And the evidence that a specific daily dose of the right collagen peptide can measurably support skin elasticity during this window — is real.

One sachet. Every day. That's the protocol.